By 2025, Cipla plans to achieve carbon and water neutrality, zero-waste to landfill, anti-microbial resistance stewardship and green chemistry.
This expansion announcement came right after raising series B funding of $27 Mn in a round led by Fundamentum Partnership, earlier this month.
Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date
New logo reflects Thyrocare’s transformation since 1996 to its current leading position at the cutting edge of Diagnostic services
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Motrin Oral Suspension, 100 mg/5 mL, of McNeil Consumer Healthcare (McNeil)
Pharmaceutical manufacturer uses Veeam solutions to accelerate mission-critical backups by 95% and restore data in minutes, not hours
Already an existing partner and supplier of ingredients to Medisca, striking this agreement with SUANFARMA involved reinforcing a well-established symbiotic relationship between two companies committed to world-class quality, service, and price
Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphoma
The acquisition is subject to customary closing conditions and necessary regulatory approvals. The financial terms of the transaction are confidential
By 2025, the company plans to achieve carbon and water neutrality, zero-waste to landfill, anti-microbial resistance stewardship and green chemistry
Subscribe To Our Newsletter & Stay Updated
